Real-World Study Shows Vandetanib and Cabozantinib Effective for Advanced MTC – Oncology Learning Network

CONTEXT:  Treatment regimes shown to be effective in advanced medullary thyroid cancer through this real world study.

IMPACT:  Medium

READ TIME:  2 mins


Quality Level Mean [1 – 10, 10 highest]:  7

1. “According to a real-world study, vandetanib and cabozantinib proved to be an effective first-line treatment in patients with advanced medullary thyroid cancer (MTC; Thyroid.” 

2. “The multi-tyrosine kinase inhibitors (TKIs) vandetanib and cabozantinib have been approved for the treatment of progressive MTC based on prolonged progression-free survival (PFS) in phase 3 clinical trials,” explained Viktoria F Koehler, Department of Internal Medicine IV, University Hospital, LMU Munich, Germany, and colleagues.” 

3. “Koehler and her team conducted their research by evaluating clinical characteristics, treatment regimens, efficacy, and treatment-emergent adverse events (TEAEs) of vandetanib and cabozantinib in MTC patients across four German tertiary care centers.” 

4. “At ≥24 weeks, stable disease occurred in 16 vandetanib patients and three cabozantinib patients, with the median PFS for vandetanib and cabozantinib being 17 (95% confidence interval, CI, 9.3-24.6 months) and four months (CI 3.1-4.9 months), respectively.” 

5. ““Vandetanib and cabozantinib are effective treatment options in the majority of MTC patients.” 

Source URL: https://www.oncnet.com/news/real-world-study-shows-vandetanib-and-cabozantinib-effective-advanced-mtc